(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 6.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Taysha Gene Therapies's revenue in 2025 is $7,224,000.On average, 3 Wall Street analysts forecast TSHA's revenue for 2025 to be $1,611,250,833, with the lowest TSHA revenue forecast at $1,137,707,090, and the highest TSHA revenue forecast at $1,974,887,778. On average, 2 Wall Street analysts forecast TSHA's revenue for 2026 to be $1,856,823,835, with the lowest TSHA revenue forecast at $1,738,759,892, and the highest TSHA revenue forecast at $1,974,887,778.
In 2027, TSHA is forecast to generate $1,755,932,829 in revenue, with the lowest revenue forecast at $1,755,932,829 and the highest revenue forecast at $1,755,932,829.